Source comparison
CJC-1295 No DAC & Ipamorelin: Protocol Comparison
| Protocol Type | CJC-1295 Dose | Ipamorelin Dose | Injection Frequency | Primary Application | Expected Outcome | Professional Assessment ||—|—|—|—|—|—|| Acute Recovery (Post-Competition) | 200mcg | 300mcg | Nightly for 5–7 days | High training load, competit
This comparison does not assign a generated winner or score.
- | Protocol Type | CJC-1295 Dose | Ipamorelin Dose | Injection Frequency | Primary Application | Expected Outcome | Professional Assessment ||—|—|—|—|—|—|| Acute Recovery (Post-Competition) | 200mcg | 300mcg | Nightly for 5–7 days | High training load, competition recovery, injury rehab | 30–50% faster return to baseline performance markers; reduced systemic inflammation | Best for short-term recovery bursts. Not sustainable beyond 10 days without rest || Maintenance Recovery | 100mcg | 200mcg | 3–4 nights/week (non-consecutive) | Ongoing training, chronic fatigue management | Sustained deep-sleep quality; 15–25% reduction in DOMS duration | Ideal for long-term use. Minimises receptor desensitisation || Pre-Sleep Only | 100–150mcg | 200–250mcg | Nightly before bed | Sleep architecture optimisation, CNS recovery | Improved Stage 3/4 sleep; higher morning HRV | Works synergistically with magnesium glycinate and low blue-light exposure || Injury Rehab Focus | 150–200mcg | 250–300mcg | 5 ni